Compare GERN & TPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GERN | TPB |
|---|---|---|
| Founded | 1990 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Tobacco |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1996 | 2015 |
| Metric | GERN | TPB |
|---|---|---|
| Price | $1.10 | $64.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $4.25 | ★ $118.50 |
| AVG Volume (30 Days) | ★ 5.9M | 408.8K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 0.48% |
| EPS Growth | ★ 51.85 | 45.33 |
| EPS | N/A | ★ 3.11 |
| Revenue | $1,065,000.00 | ★ $463,062,000.00 |
| Revenue This Year | $28.49 | $22.45 |
| Revenue Next Year | $44.73 | $12.73 |
| P/E Ratio | ★ N/A | $21.51 |
| Revenue Growth | N/A | ★ 28.39 |
| 52 Week Low | $1.04 | $54.17 |
| 52 Week High | $2.01 | $146.90 |
| Indicator | GERN | TPB |
|---|---|---|
| Relative Strength Index (RSI) | 32.01 | 52.96 |
| Support Level | $1.08 | $54.43 |
| Resistance Level | $1.26 | $91.03 |
| Average True Range (ATR) | 0.05 | 2.63 |
| MACD | -0.00 | 1.66 |
| Stochastic Oscillator | 8.33 | 68.21 |
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.